Shopping Cart 0
Cart Subtotal
AED 0

GeoVax Labs Inc (GOVX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
AED 918

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
AED 1835

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
AED 2753

Details

Summary

GeoVax Labs Inc (GeoVax) develops human vaccines for diseases caused by human immunodeficiency virus (HIV), cancer and other infectious diseases using Modified Vaccinia Ankara Virus-Like Particle (MVA-VLP) vaccine platform. The company's vaccine development programs focus on HIV, Zika virus and hemorrhagic fever viruses (Ebola, Marburg, Lassa fever) and for cancer immunotherapy. Its advanced vaccines under development act against the clade B subtype of the HIV virus and clade C subtype. GeoVax developed its proprietary vaccine technology in collaboration with the U.S. National Institutes of Health (NIH), Centers for Disease Control and Prevention (CDC) and Emory University. GeoVax is headquartered in Smyrna, Georgia, the US.

GeoVax Labs Inc (GOVX)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

GeoVax Labs Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

GeoVax Labs Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

GeoVax Labs Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

GeoVax Labs Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

GeoVax Labs Inc, Medical Devices Deals, 2012 to YTD 2018 10

GeoVax Labs Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

GeoVax Labs Inc, Pharmaceuticals & Healthcare, Deal Details 13

Partnerships 13

GeoVax Labs and PharmaJet Enter into Partnership 13

Geovax Labs and Emory University Enter into Partnership 14

GeoVax Labs Enters into Agreement with CaroGen 15

GeoVax Labs Enters into Agreement with Vaxeal 16

GeoVax Labs Enters into Agreement with Scripps Research Institute and Institute of Human Virology 17

GeoVax Labs Enters into Partnership with American Gene Technologies 18

GeoVax Labs Research Agreement with Georgia State University Research Foundation 19

GeoVax Labs Enters into Research Agreement with Burnet Institute 20

GeoVax Labs Enters into Co-Development Agreement with ViaMune 21

GeoVax Labs Enters into Research Agreement with Centers for Disease Control and Prevention 22

GeoVax Labs Enters into R&D Agreement with USAMRIID 23

GeoVax Labs Enters into Research Agreement with University of Georgia 24

GeoVax Labs Enters into Research Agreement with University of Pittsburgh 25

GeoVax Labs Enters into Research Agreement with National Institute of Allergy and Infectious Diseases 26

Licensing Agreements 27

GeoVax Labs Enters into Licensing Agreement with Valneva 27

Equity Offering 28

GeoVax Labs to Issue Up to 66,666,666 Series D Convertible Preferred Stock 28

GeoVax Labs Issues 1,000 Shares in Private Placement of Series D Preferred Stock 29

GeoVax Labs Raise Funds through in Public Offering of Shares up on Exercise of Warrants 30

GeoVax Labs Raises USD6 Million in Private Placement 31

GeoVax Labs Completes Private Placement Of Shares For USD 1.6 Million 32

GeoVax Completes Private Placement Of Series A Convertible Preferred Stock For USD 2.2 Million 33

GeoVax Completes Second Tranche Of Private Placement Of Units For USD 0.25 Million 34

GeoVax Labs Inc-Key Competitors 35

GeoVax Labs Inc-Key Employees 36

GeoVax Labs Inc-Locations And Subsidiaries 37

Head Office 37

Other Locations & Subsidiaries 37

Recent Developments 38

Financial Announcements 38

Aug 07, 2018: GeoVax reports 2018 second quarter financial results and provides corporate update 38

May 03, 2018: GeoVax Reports 2018 First Quarter Financial Results and Development Program Updates 40

Mar 23, 2018: GeoVax Announces 2017 Year-End Financial Results 42

Nov 09, 2017: GeoVax Reports 2017 Third Quarter Financial Results and Development Program Updates 43

Aug 07, 2017: GeoVax Reports 2017 Second Quarter Financial Results Results and Provides Corporate Update 45

May 08, 2017: GeoVax Reports 2017 First Quarter Financial Results and Development Program Updates 47

Mar 24, 2017: GeoVax Reports 2016 Year-End Financial Results 48

Corporate Communications 49

Aug 14, 2018: GeoVax names David Dodd as Chairman, President and Chief Executive Officer 49

Product News 50

10/09/2017: GeoVax Chief Scientific Officer to Deliver Two Talks at World Vaccine Congress 50

08/30/2017: GeoVax Presents Preliminary Data for Cancer Vaccine 51

04/03/2017: GeoVax Awarded USD 658,000 NIH Grant for its HIV Vaccine Program 52

01/16/2018: GeoVax Publishes Ebola Vaccine Study Results in Nature's Scientific Reports 53

Clinical Trials 54

Jan 23, 2017: GeoVax Announces Initiation of HIV Human Clinical Trial 54

Other Significant Developments 55

Mar 28, 2018: GeoVax Provides Vaccine Development Update 55

Mar 27, 2017: GeoVax Reports on Vaccine Development Progress 58

Appendix 60

Methodology 60

About GlobalData 60

Contact Us 60

Disclaimer 60


List Of Figure

List of Figures

GeoVax Labs Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

GeoVax Labs Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

GeoVax Labs Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

GeoVax Labs Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

GeoVax Labs Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

GeoVax Labs Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

GeoVax Labs Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

GeoVax Labs Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

GeoVax Labs Inc, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

GeoVax Labs Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

GeoVax Labs Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

GeoVax Labs Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

GeoVax Labs Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

GeoVax Labs Inc, Deals By Therapy Area, 2012 to YTD 2018 9

GeoVax Labs Inc, Medical Devices Deals, 2012 to YTD 2018 10

GeoVax Labs Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

GeoVax Labs and PharmaJet Enter into Partnership 13

Geovax Labs and Emory University Enter into Partnership 14

GeoVax Labs Enters into Agreement with CaroGen 15

GeoVax Labs Enters into Agreement with Vaxeal 16

GeoVax Labs Enters into Agreement with Scripps Research Institute and Institute of Human Virology 17

GeoVax Labs Enters into Partnership with American Gene Technologies 18

GeoVax Labs Research Agreement with Georgia State University Research Foundation 19

GeoVax Labs Enters into Research Agreement with Burnet Institute 20

GeoVax Labs Enters into Co-Development Agreement with ViaMune 21

GeoVax Labs Enters into Research Agreement with Centers for Disease Control and Prevention 22

GeoVax Labs Enters into R&D Agreement with USAMRIID 23

GeoVax Labs Enters into Research Agreement with University of Georgia 24

GeoVax Labs Enters into Research Agreement with University of Pittsburgh 25

GeoVax Labs Enters into Research Agreement with National Institute of Allergy and Infectious Diseases 26

GeoVax Labs Enters into Licensing Agreement with Valneva 27

GeoVax Labs to Issue Up to 66,666,666 Series D Convertible Preferred Stock 28

GeoVax Labs Issues 1,000 Shares in Private Placement of Series D Preferred Stock 29

GeoVax Labs Raise Funds through in Public Offering of Shares up on Exercise of Warrants 30

GeoVax Labs Raises USD6 Million in Private Placement 31

GeoVax Labs Completes Private Placement Of Shares For USD 1.6 Million 32

GeoVax Completes Private Placement Of Series A Convertible Preferred Stock For USD 2.2 Million 33

GeoVax Completes Second Tranche Of Private Placement Of Units For USD 0.25 Million 34

GeoVax Labs Inc, Key Competitors 35

GeoVax Labs Inc, Key Employees 36

GeoVax Labs Inc, Subsidiaries 37

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

GeoVax Labs Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

GeoVax Labs Inc (GeoVax) develops human vaccines for diseases caused by human immunodeficiency virus (HIV), cancer and other infectious diseases using Modified Vaccinia Ankara Virus-Like Particle (MVA-VLP) vaccine platform. The company's vaccine development programs focus on HIV, Zika virus and hemorrhagic fever viruses (Ebola, Marburg, Lassa fever) and for cancer immunotherapy. Its advanced vaccines under development act against the clade B subtype of the HIV virus and clade C subtype. GeoVax developed its proprietary vaccine technology in collaboration with the U.S. National Institutes of Health (NIH), Centers for Disease Control and Prevention (CDC) and Emory University. GeoVax is headquartered in Smyrna, Georgia, the US.

GeoVax Labs Inc (GOVX)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

GeoVax Labs Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

GeoVax Labs Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

GeoVax Labs Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

GeoVax Labs Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

GeoVax Labs Inc, Medical Devices Deals, 2012 to YTD 2018 10

GeoVax Labs Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

GeoVax Labs Inc, Pharmaceuticals & Healthcare, Deal Details 13

Partnerships 13

GeoVax Labs and PharmaJet Enter into Partnership 13

Geovax Labs and Emory University Enter into Partnership 14

GeoVax Labs Enters into Agreement with CaroGen 15

GeoVax Labs Enters into Agreement with Vaxeal 16

GeoVax Labs Enters into Agreement with Scripps Research Institute and Institute of Human Virology 17

GeoVax Labs Enters into Partnership with American Gene Technologies 18

GeoVax Labs Research Agreement with Georgia State University Research Foundation 19

GeoVax Labs Enters into Research Agreement with Burnet Institute 20

GeoVax Labs Enters into Co-Development Agreement with ViaMune 21

GeoVax Labs Enters into Research Agreement with Centers for Disease Control and Prevention 22

GeoVax Labs Enters into R&D Agreement with USAMRIID 23

GeoVax Labs Enters into Research Agreement with University of Georgia 24

GeoVax Labs Enters into Research Agreement with University of Pittsburgh 25

GeoVax Labs Enters into Research Agreement with National Institute of Allergy and Infectious Diseases 26

Licensing Agreements 27

GeoVax Labs Enters into Licensing Agreement with Valneva 27

Equity Offering 28

GeoVax Labs to Issue Up to 66,666,666 Series D Convertible Preferred Stock 28

GeoVax Labs Issues 1,000 Shares in Private Placement of Series D Preferred Stock 29

GeoVax Labs Raise Funds through in Public Offering of Shares up on Exercise of Warrants 30

GeoVax Labs Raises USD6 Million in Private Placement 31

GeoVax Labs Completes Private Placement Of Shares For USD 1.6 Million 32

GeoVax Completes Private Placement Of Series A Convertible Preferred Stock For USD 2.2 Million 33

GeoVax Completes Second Tranche Of Private Placement Of Units For USD 0.25 Million 34

GeoVax Labs Inc-Key Competitors 35

GeoVax Labs Inc-Key Employees 36

GeoVax Labs Inc-Locations And Subsidiaries 37

Head Office 37

Other Locations & Subsidiaries 37

Recent Developments 38

Financial Announcements 38

Aug 07, 2018: GeoVax reports 2018 second quarter financial results and provides corporate update 38

May 03, 2018: GeoVax Reports 2018 First Quarter Financial Results and Development Program Updates 40

Mar 23, 2018: GeoVax Announces 2017 Year-End Financial Results 42

Nov 09, 2017: GeoVax Reports 2017 Third Quarter Financial Results and Development Program Updates 43

Aug 07, 2017: GeoVax Reports 2017 Second Quarter Financial Results Results and Provides Corporate Update 45

May 08, 2017: GeoVax Reports 2017 First Quarter Financial Results and Development Program Updates 47

Mar 24, 2017: GeoVax Reports 2016 Year-End Financial Results 48

Corporate Communications 49

Aug 14, 2018: GeoVax names David Dodd as Chairman, President and Chief Executive Officer 49

Product News 50

10/09/2017: GeoVax Chief Scientific Officer to Deliver Two Talks at World Vaccine Congress 50

08/30/2017: GeoVax Presents Preliminary Data for Cancer Vaccine 51

04/03/2017: GeoVax Awarded USD 658,000 NIH Grant for its HIV Vaccine Program 52

01/16/2018: GeoVax Publishes Ebola Vaccine Study Results in Nature's Scientific Reports 53

Clinical Trials 54

Jan 23, 2017: GeoVax Announces Initiation of HIV Human Clinical Trial 54

Other Significant Developments 55

Mar 28, 2018: GeoVax Provides Vaccine Development Update 55

Mar 27, 2017: GeoVax Reports on Vaccine Development Progress 58

Appendix 60

Methodology 60

About GlobalData 60

Contact Us 60

Disclaimer 60


List Of Figure

List of Figures

GeoVax Labs Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

GeoVax Labs Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

GeoVax Labs Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

GeoVax Labs Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

GeoVax Labs Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

GeoVax Labs Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

GeoVax Labs Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

GeoVax Labs Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

GeoVax Labs Inc, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

GeoVax Labs Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

GeoVax Labs Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

GeoVax Labs Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

GeoVax Labs Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

GeoVax Labs Inc, Deals By Therapy Area, 2012 to YTD 2018 9

GeoVax Labs Inc, Medical Devices Deals, 2012 to YTD 2018 10

GeoVax Labs Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

GeoVax Labs and PharmaJet Enter into Partnership 13

Geovax Labs and Emory University Enter into Partnership 14

GeoVax Labs Enters into Agreement with CaroGen 15

GeoVax Labs Enters into Agreement with Vaxeal 16

GeoVax Labs Enters into Agreement with Scripps Research Institute and Institute of Human Virology 17

GeoVax Labs Enters into Partnership with American Gene Technologies 18

GeoVax Labs Research Agreement with Georgia State University Research Foundation 19

GeoVax Labs Enters into Research Agreement with Burnet Institute 20

GeoVax Labs Enters into Co-Development Agreement with ViaMune 21

GeoVax Labs Enters into Research Agreement with Centers for Disease Control and Prevention 22

GeoVax Labs Enters into R&D Agreement with USAMRIID 23

GeoVax Labs Enters into Research Agreement with University of Georgia 24

GeoVax Labs Enters into Research Agreement with University of Pittsburgh 25

GeoVax Labs Enters into Research Agreement with National Institute of Allergy and Infectious Diseases 26

GeoVax Labs Enters into Licensing Agreement with Valneva 27

GeoVax Labs to Issue Up to 66,666,666 Series D Convertible Preferred Stock 28

GeoVax Labs Issues 1,000 Shares in Private Placement of Series D Preferred Stock 29

GeoVax Labs Raise Funds through in Public Offering of Shares up on Exercise of Warrants 30

GeoVax Labs Raises USD6 Million in Private Placement 31

GeoVax Labs Completes Private Placement Of Shares For USD 1.6 Million 32

GeoVax Completes Private Placement Of Series A Convertible Preferred Stock For USD 2.2 Million 33

GeoVax Completes Second Tranche Of Private Placement Of Units For USD 0.25 Million 34

GeoVax Labs Inc, Key Competitors 35

GeoVax Labs Inc, Key Employees 36

GeoVax Labs Inc, Subsidiaries 37

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

GeoVax Labs Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.